Intrinsic Therapeutics Announces New CPT Code for Barricaid Device
Intrinsic Therapeutics, Inc., known for the innovative Barricaid Annular Closure Device, has recently made headlines with the release of a new Category I CPT code 63032. This development, effective starting January 1, 2026, signifies a pivotal advancement in the treatment of patients undergoing lumbar discectomy.
Details of the New CPT Code
The newly introduced CPT code specifically addresses the adjunctive placement of a bone-anchored annular closure device following a lumbar discectomy in patients with significant annular defects. According to the CPT long descriptor, it states: "with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (list separately in addition to the code for primary procedure)." This clarity allows for more accurate billing and coding, ensuring patients receive the necessary attention and treatment without the worry of insurance claim issues.
Significance of this Development
April Spillane, Vice President of Health Economics at Intrinsic Therapeutics, commented, "For over twenty years, the spine community has been striving for effective solutions for discectomy patients at high risk of reherniation. The introduction of this CPT code marks a significant breakthrough in improving care for these patients. With this code, surgeons can now accurately document the specific repair work involved when using Barricaid after a discectomy, potentially paving the way for increased patient access to this vital treatment."
Current Guidelines and Recommendations
With the ISASS 2025 guidelines now advising annular closure for appropriately selected patients, Intrinsic Therapeutics is urging surgeons and payors across the nation to revise their systems to accommodate this new CPT code 63032. This adjustment not only aligns with best practices but also enhances patient care.
Industry Reactions
Greg Lambrecht, the founder of Barricaid, shared his enthusiasm about the newly established CPT code. "This recognition underscores the significant advancement that Barricaid represents in standard care for discectomy patients. It showcases the collective effort of our dedicated team, specialized societies, and the spine surgeon community. I am thrilled that patients now have a streamlined pathway to receive the treatment they need."
About Barricaid
Barricaid is a proprietary medical device designed to significantly reduce the need for reoperations due to reherniations, boasting an impressive 81% reduction in lumbar discectomy patients with large annular defects. Since its inception, Barricaid has been successfully implanted in nearly 13,000 patients and is backed by robust clinical research across eight distinct patient populations. This includes two randomized controlled trials and six single-arm studies, with notable findings published in leading medical journals.
One prominent multicenter, Level I randomized controlled trial demonstrated superior outcomes for patients using Barricaid compared to those undergoing discectomy alone, providing five-year follow-up results that have bolstered confidence in its effectiveness.
Clinical Studies and Research
Barricaid's efficacy in preventing reherniation has been supported through various studies, with some results available beyond FDA indications, measuring success at a minimum of one year post-operation. These findings are derived from a minimum of 20 Barricaid subjects, emphasizing the device's safety and reliability.
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc., and the CPT code is recognized as a registered trademark of the American Medical Association (AMA), further highlighting the collaboration between industry innovators and medical coding authorities to enhance patient care.
Frequently Asked Questions
What is the new CPT code introduced by Intrinsic Therapeutics?
The new CPT code is 63032, used for billing the addition of a bone-anchored annular closure device after a lumbar discectomy.
Why is this CPT code important?
This code allows for accurate billing, ensuring that patients have access to the necessary treatment without issues related to insurance claims.
How does Barricaid work?
Barricaid is designed to reduce the likelihood of reherniation following lumbar discectomy by effectively sealing the annular defect.
What do recent guidelines say about annular closure?
The ISASS 2025 guidelines recommend annular closure for selected patients, emphasizing its importance in spinal surgeries.
How many patients have received Barricaid?
Nearly 13,000 patients have been treated with Barricaid, showcasing its widespread use and acceptance in the medical community.
